Short answer
Intellia Therapeutics, Inc. (NTLA) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Investor presentation focused on preparing lonvo-z for patients with hereditary angioedema.
Intellia Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Investor presentation focused on preparing lonvo-z for patients with hereditary angioedema
- Event provides an update on commercial readiness and potential launch execution for lonvo-z
- Exhibit 99.1 contains the detailed presentation materials for investors
Item EX-99.1 · Exhibit EX-99.1
- Lonvo-z BLA accepted with FDA priority review, PDUFA decision target March 10, 2027, accelerating potential commercial launch
- Phase 3 HAELO met primary and key secondary endpoints, reducing attack rate 62% versus 11% with placebo
- Attack-free weeks increased 87%, with odds ratio 12.8 and p<0.0001, supporting a potentially differentiated one-time treatment
- Lonvo-z 50 mg showed durable effects through 4 years, with 100% of patients LTP-free at latest cutoff
- Commercial readiness work is underway, but approval and launch remain contingent on FDA review and manufacturing execution
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Intellia Therapeutics, Inc. 8-K filings
Get the next NTLA 8-K as it lands
Follow NTLA for push alerts, or ask the research agent what this filing means.